Home › Funds › Gibbs Wealth Management › VRTX

Gibbs Wealth Management position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Gibbs Wealth Management reported holding 6,074 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$3.2M, representing 0.34% of its reported portfolio and ranking #46 among its reported holdings. Gibbs Wealth Management has disclosed VRTX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)6.07K sh
Reported value held$3.18M
Portfolio Weight0.34%
First reportedQ4 2024
Last changeAdd
Updated2026-10-22

Last updated: 2026-10-22 · Source: SEC EDGAR Form 13F-HR

How Gibbs Wealth Management's VRTX position evolved

Gibbs Wealth Management first disclosed a stake in VRTX in Q4 2024 at 586 shares (US$236K). The position peaked in Q3 2026 at 6,074 shares, worth US$3.2M. Across 8 filings, Gibbs Wealth Management increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 6,074 shares valued at US$3.2M — an increase of 592 shares quarter over quarter.. Notable position changes include a 70% increase in Q1 2025 (shares fell 8% over the following quarter), a 44% increase in Q2 2025 (shares fell 12% over the following quarter), a 357% increase in Q1 2026 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 586 $235.98K New
Q1 2025 998 $483.85K Add
Q2 2025 1.43K $637.97K Add
Q3 2025 1.22K $476.23K Reduce
Q4 2025 1.24K $572.87K Add
Q1 2026 5.65K $2.52M Add
Q2 2026 5.48K $2.72M Reduce
Q3 2026 6.07K $3.18M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Gibbs Wealth Management held VRTX?

Gibbs Wealth Management has disclosed VRTX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Gibbs Wealth Management's current position in VRTX?

As of Q3 2026, Gibbs Wealth Management holds 6.07K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $3.18M, representing 0.34% of its reported portfolio and ranking #46.

Has Gibbs Wealth Management been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Gibbs Wealth Management increased its position in VRTX. The position peaked in Q3 2026 at 6.07K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.